

EXHIBIT¹⁰

Year	Valency/ Serotypes	Carrier	Dosage of saccharide/ Protein: saccharide ratio	Reference
Pfizer/Wyeth Pharmaceuticals				
1994	Bivalent 6A and 23F, OS and CPS and with or without linker	CRM197	2 and 10 µg of each serotype	Steinboff, M.C. et al. (1994) <i>A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics</i> . Pediatr. Infect. Dis. J. Vol. 13(5) pp 368-372.
1995	Pentavalent 6B, 14, 18C, 19 and 23F	CRM197	10 µg of each serotypes	Chlu, S.S. et al. (1995) <i>Safety and immunogenicity of a pentavalent pneumococcal conjugate vaccine (PCV) in healthy toddlers</i> . Presented at the 35 th Inter= Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G71 p 171.
	Pentavalent 6B, 14, 18C, 19F and 23F	CRM197	0.5, 2 and 5 µg of each serotype	Daum, R.S. et al. (1995) <i>Immunogenicity of S Pneumoniae oligo- and polysaccharide- CRM197 conjugate vaccines in healthy US infants</i> . Presented at the 35 th Intersc Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G65 page 170.
1996	Bivalent 6A and 23F	CRM197	2 and 10µg of each serotype	O'Brien, K.L. et al. (1996) <i>Immunologic priming of young children by pneumococcal glycoprotein conjugate but not polysaccharide, vaccines</i> . Pediatr. Infect. Dis. J. Vol. 15(5) pp 425-430.
	Pentavalent 6B, 14, 18C, 19F and 23F together with Tetramune	CRM197	10 µg of each serotype Ratio 1-3:1, overall ratio 2:1	Ahman, H. et al. (1996) <i>Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants</i> . The Pediatric Infectious Disease Journal. Vol. 15(2) pp134-139.
	Heptavalent 4, 6B, 9V, 14, 18C, 19F, 23F ¹¹	CRM197	2 µg of serotypes 4, 9V, 14, 18C, 19F, 23F and 4 µg of serotype 6B	Rennels, M.B. et al. (1996) <i>Abstract from Immunogenicity and Safety of 7-Valent Pneumococcal-CRM-197 Conjugate Vaccine. Pediatric Research</i> , Vol. 39(4) part 2 p 183A. Abstr 1082.

¹⁰ Note: In this table only the name of the current company is given. Wyeth Pharmaceuticals, recently purchased by Pfizer, was formerly Praxis Biologics-Lederle Laboratories. Sanofi-Pasteur was formerly Pasteur Merieux and Connaught Laboratories.

¹¹ Approved and commercialized under the trademark Prevnar®.

Year	Valency/ Serotypes	Carrier	Dosage of saccharide/ Protein: saccharide ratio	Reference
1997	Pentavalent 6B, 14, 18C, 19F and 23F	CRM197	10 µg of each serotype Ratio 0.5-1:1	Shelly, M.A. <i>et al.</i> (1997) <i>Comparison of pneumococcal polysaccharide and CRM197 conjugated pneumococcal oligosaccharide vaccines In young and elderly adults</i> Infection & Immunity Vol. 65(1) pp 242-247.
Sanofi Pasteur				
1994	Monovalent 19F	DT	10 µg of each serotype	Kennedy, D. <i>et al.</i> (1994) <i>Immunologic response of 12-18 months old children to licensed pneumococcal polysaccharide vaccine (PS) primed with Streptococcus pneumoniae 19F conjugate vaccine (CV)</i> . Presented at the 34 th Intersc Conf Antimicrob. Agents and Chemotherapy Orlando Abstr G88 p 236.
	Tetavalent 6B, 14, 19F and 23F	DT or TT	10 µg of each serotype	Nieminen, T. <i>et al.</i> (1994) <i>Mucosal and serum immune response to tetraivalent pneumococcal (SPn) conjugate vaccines (SpnD and SpnT) In adults</i> . Presented at the 34 th Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstr G89 p 236.
	Tetavalent 6B, 14, 19F and 23F	T1	1, 3 and 10 µg of each serotype	Portier, H. <i>et al.</i> (1994) <i>Serum antibody response to a tetraivalent pneumococcal tetanus toxoid conjugate vaccine in adult volunteers</i> . Presented at the 34 th Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstr G91 p 236.
1995		-		
1996	Octavalent 3, 4, 6B, 9V, 14, 18C, 19F and 23F	TT DT	1 µg of each serotype 3 µg of each serotype	Ahman, H. <i>et al.</i> (1996) <i>Immunogenicity of octavalent pneumococcal conjugate vaccines in Finnish infants</i> . ICAAC Abstract G40, page 150.
Merck Sharp & Dohm				
1994	Monovalent 14	OMPc	0.5, 1, 2.5 and 5 µg of each serotype	Keyserling, H. <i>et al.</i> (1994) <i>Immunogenicity of type 14 conjugate vaccine in infants</i> . Presented at the annual meeting of the American Pediatric Society/Society for Pediatric Research Seattle WA. Abstract 1087, p184A.
	Heptavalent 4, 6B, 9V, 14, 18C, 19F and 23F	OMPc	1 µg of serotypes 14, 18C, 19F, 23F, 4, 9V and 2.5 µg of serotype 6B	Kennedy, D. <i>et al.</i> (1994) <i>Immunologic response to licensed pneumococcal polysaccharide vaccine (PS) In infants primed with heptavalent Streptococcus pneumoniae conjugated vaccine</i> . Presented at the 34 th Intersc. Conf. Antimicrob. Agents In Chemotherapy, Orlando Abstract G90 p 236.

Year	Valency/ Serotypes	Carrier	Dosage of saccharide/ Protein: saccharide ratio	Reference
1995	Tetavalent 68, 14, 19F and 23F	OMPc	1 µg of each serotype Ratio: 5.9-9.1:1	Käyhty, H. et al. (1995) <i>Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children</i> . J. Infect. Diseases Vol. 172 pp 1273-1278.
1996	Heptavalent 4, 6B, 9V, 14, 18C, 19F and 23F	OMPc	1 µg of serotypes 4, 14, 18C and 23F, 1.5 µg of serotype 9V, 2 µg of serotype 19F and 3.5 µg of serotype 68 Ratio: 7.8:1 (11µg PS and 85 pp OMPc)	Dagen, Ron et al. (1996) <i>Reduction of Nasopharyngeal Carriage of Pneumococci during the Second Year of Life by a Heptavalent Conjugate Pneumococcal Vaccine</i> . J. Infect. Diseases Vol. 174 pp 1271-1278.
1997	Heptavalent 4, 68, 9V, 14, 18C, 19F and 23F	OMPc	In Lot A - total polysaccharide - 17.6 µg and total OMPc - 123 µg In Lot B total polysaccharide - 16.1 µg and total OMPc - 140 µg	Greenberg D.P. et al. (1997) <i>Factors influencing the immunogenicity of a pneumococcal conjugate vaccine in infants</i> . Pediatr. Res. Vol. 41 p121 abstr 709.